Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New headband zaps migraine pain in clinical trial

NCT ID NCT07015125

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new wearable device that uses gentle electrical stimulation on the head and neck to relieve migraine pain. 160 people with migraines used the device during attacks, and researchers compared real stimulation to a sham (inactive) treatment. The goal was to see if the device provides safe and effective pain relief within one to two hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

160 people

The number who actually took part.

Started

Jun 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of migraine with or without aura, identified via participant-provided medical records. * Average migraine pain is 4 or more on the 0-10 Numerical Rating Scale (NRS) for pain. * Passes ID-Migraine pre-screening questions and has ID-Migraine score ≥ 2: a. ID-Migraine pre-screening questions: i. How many headaches have participants experienced within the previous 3 months? * Needs to be ≥ 6 headaches ii. Do the headaches that participants experience limit the ability to work, study, or enjoy life, or does the participant wish to speak with a healthcare professional about the headaches? (yes / no) * Participant needs to respond "yes" b. ID-Migraine questions: i. Over the last 3 months, did participants have any of the following with headaches? * Felt nauseated or sick to stomach (yes \[1\] / no \[0\]) * Light bothered them (a lot more than when headaches are not present)? (yes \[1\] / no \[0\]) * Headaches limited the ability to work, study, or do what needed to be done? (yes \[1\] / no \[0\]) * Able to understand and provide informed consent. * Age 18 and older. * US resident. * Has experienced migraines for at least 1 year prior to recruitment. * Onset of migraines occurred at age 50 years or younger. * Average of at least 2 migraines per month of moderate to severe intensity. * Is either on a) no medications or b) a stable dose of migraine-preventative medication for at least 2 months prior to recruitment. * Willing to refrain from altering preventive medication for migraines (or from using botox), commit to using Enso as the first-line treatment, and wait at least 2 hours after Enso treatment before using any additional abortives during the study period. * Participants must own an iPhone with iOS 15 or newer, or an Android phone with Android 9 or newer, with Bluetooth capability and access to either the Apple App Store (for iOS devices) or Google Play Store (for Android devices). * Has an email account. Exclusion Criteria: * Typical migraine pain is \< 4 out of 10 on the 0-10 NRS. * Currently institutionalized. * Currently is or has ever been a Hinge Health member. * Use of antipsychotic medication up to 3 months before study recruitment. * Diagnosis of cancer/malignant tumors in the last 5 years. * Cognitive, behavioral, neurologic, or psychiatric disorder (e.g., dementia, Parkinson's, schizophrenia, stroke) that may interfere with the study or prevent the subject from complying with the requirements of the protocol. * Has epilepsy. * Has a history of major cardiovascular events such as strokes, arrhythmias, or myocardial infarction. * Has a history of major migraine complications such as migrainous infarction or migraine aura-triggered seizure * Diagnosed with secondary headache disorders including medication overuse headaches * History of opioid, alcohol, or drug abuse in the last 1 year. * Has a cardiac pacemaker, implanted defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other implanted electronic device. * Has a metal implant in the upper extremities or head. * Has a history of major head or neck surgeries. * Pregnant. * Currently participating or has participated in a study with an investigational compound or device within the last 30 days before the screening visit. * Currently using a TENS device to treat migraines. * Received supraorbital nerve blocks or Botox treatment within 4 months prior to recruitment. * Insufficient proficiency with the English language to take part in study procedures or complete online surveys. * Planning to travel outside of the US within three months after consenting to the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hinge Health, Inc.

    San Francisco, California, 94105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.